Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
US12071621B2 · kind B2 · utility
1Cited by
78References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 4, 2023 |
| Grant date | Aug 27, 2024 |
| Priority date | — |
| Expiry date | Apr 4, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are antibody oligonucleotide conjugates and pharmaceutical compositions that induce an alteration in an incorrectly spliced dystrophin mRNA transcript to induce exon 44 skipping. Also described herein include methods for treating muscle dystrophy including Duchenne muscular dystrophy that comprises administering antibody oligonucleotide conjugates or a pharmaceutical composition that induces alteration in an incorrectly spliced dystrophin mRNA transcript to induce exon 44 skipping.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.